Loading
DNA-crosslinking chemotherapy is especially effective in tumours that cannot repair double-strand breaks.
This combination pairs Platinum agents with tumours carrying BRCA1 / BRCA2 (HRD) defects, because DNA-crosslinking chemotherapy is especially effective in cells that cannot repair double-strand breaks. The mechanism is that interstrand crosslinks need homologous recombination to repair, so HRD cells accumulate lethal double-strand breaks, as described in the DNA damage response & homologous recombination pathway. Multiple randomised trials support it: Carboplatin raises pathological complete response in Triple-negative breast cancer (TNBC) in GeparSixto and BrighTNess, with greater benefit in BRCA-mutant or HRD tumours. In Ovarian cancer, platinum sensitivity defines the treatable population, and the pairing is linked from the TNBC, Platinum agents and BRCA1 / BRCA2 (HRD) entries.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Ovarian cancer, Triple-negative breast cancer (TNBC).
Shares Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Carboplatin, Triple-negative breast cancer (TNBC).
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Carboplatin.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Ovarian cancer, Triple-negative breast cancer (TNBC).
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Ovarian cancer, Triple-negative breast cancer (TNBC).